Analyst Rating Update on Achillion Pharmaceuticals (ACHN)

Achillion Pharmaceuticals (NASDAQ:ACHN) : 3 brokerage houses believe that Achillion Pharmaceuticals (NASDAQ:ACHN) is a Strong Buy at current levels. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Achillion Pharmaceuticals (NASDAQ:ACHN). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 6 Wall Street Analysts endorse the stock as a Buy with a rating of 2.33.

Achillion Pharmaceuticals (NASDAQ:ACHN) : Average target price received by Achillion Pharmaceuticals (NASDAQ:ACHN) is $9.5 with an expected standard deviation of $3.39. The most aggressive target on the stock is $16, whereas the most downbeat target is $7. 6 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy. Also, Equity analysts at the Brokerage firm Leerink Swann maintains its rating on Achillion Pharmaceuticals (NASDAQ:ACHN). The rating major has initiated the coverage with market perform rating on the shares. The Analysts at Leerink Swann raises the price target from $7 per share to $9 per share. The rating by the firm was issued on May 4, 2016.

Achillion Pharmaceuticals (NASDAQ:ACHN): stock turned positive on Tuesday. Though the stock opened at $7.66, the bulls momentum made the stock top out at $7.92 level for the day. The stock recorded a low of $7.66 and closed the trading day at $7.78, in the green by 4.01%. The total traded volume for the day was 1,716,741. The stock had closed at $7.48 in the previous days trading.

In an insider trading activity, Fenton Mary Kay, officer (Chief Financial Officer) of Achillion Pharmaceuticals Inc, unloaded 43,500 shares at an average price of $10.08 on December 28, 2015. The total amount of the transaction was worth $438,480, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *